Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that the U.S. Patent and ...

Researchers studying gene expression have access to vast amounts of data from cells or tissues. This is thanks to advances in ...

NIH grant funds immersive program to give M.D., Ph.D. postdoctoral fellows hands-on training in cancer drug development Ph.D.

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.